The Fibrosis and Immunological Features of Hypochlorous Acid Induced Mouse Model of Systemic Sclerosis.
Meng M, Tan J, Chen W, Du Q, Xie B, Wang N, Zhu H, Wang K.
Front Immunol. 2019 Aug 20;10:1861. doi: 10.3389/fimmu.2019.01861. eCollection 2019.
PMID:31481954
Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.
Gauthier ID, Macleod CA, Sathiadoss P, McGrath TA, Nair V, Schieda N.
Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.
Kanal E, Patton TJ, Krefting I, Wang C.
AJNR Am J Neuroradiol. 2020 Mar;41(3):393-399. doi: 10.3174/ajnr.A6448. Epub 2020 Feb 27.
PMID:32115422
[From renal crisis to lung fibrosis - systemic sclerosis in the course of time].
Jahns KM, Dreher M, Triantafyllias K, Haßdenteufel L, Schwarting A.
Dtsch Med Wochenschr. 2025 Aug;150(16):975-979. doi: 10.1055/a-2615-9127. Epub 2025 Aug 5.
PMID:40763754
Nephrogenic systemic fibrosis: an emerging threat among renal patients.